Rheumatology Archives - Page 5 of 5

Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends

Authors: C B Atzinger, J J Guo Published: American health & drug benefits, 2017 View publication Background Spending on biologic drugs is a significant driver of drug expenditures for payers in private...

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-? inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

Authors: D Aletaha; SJ Snedecor; V Ektare; M Xue; Y Bao; V Garq Published: ClinicoEconomics and outcomes research, 2017 View publication Objective To compare the real-world, 5-year clinical and cost impact of...

Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients

Authors: S. Müller; T Wilke; A Fuchs; U Maywald; JP Flacke; H Heinisch; K Krüger Published: Patient preference and adherence, 2017 View publication Objective This study aimed to assess the level of...

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis

Authors: T Wilke, S Mueller, S C Lee, I Majer, M Heisen Published: BMC musculoskeletal disorders, 2017 View publication Background Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far...

News